Protocol Ledger

NCT05112991 · Phase II · RECRUITING

Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer

Interventional Phase II clinical trial protocol NCT05112991 sponsored by 3D Medicines (Sichuan) Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-03-04 Enrollment: 108 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05112991
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)108 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05112991
Protocol FieldVerified Registry Value
NCT IdentifierNCT05112991
Consolidated Lead Sponsor3D Medicines (Sichuan) Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment108 participants (ESTIMATED)
Registered Start Date2022-03-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05112991
Hospital Research SiteLocationSite Profile
Beijing Cancer HospitalBeijing, ChinaOpen Hospital Dossier ->
Fujian Cancer HospitalFuzhou, ChinaOpen Hospital Dossier ->
Sun Yat-sen Memorial HospitalGuangzhou, ChinaOpen Hospital Dossier ->
Henan Cancer HospitalZhengzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI